Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs has continued its on-market share buy-back program, updating the market with a daily notification to the ASX. The company reported that it has repurchased a total of 4,270,516 ordinary fully paid shares prior to the latest trading day.
On the previous day alone, the company bought back an additional 200,000 shares under the existing buy-back mandate first notified in October 2025. The ongoing buy-back reduces the number of shares on issue and may support earnings per share and capital management objectives for existing shareholders.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare diagnostics sector, providing pathology and laboratory testing services. The company focuses on clinical lab services across Australia, supporting hospitals, medical practitioners, and patients with routine and specialized diagnostic testing.
Average Trading Volume: 674,838
Technical Sentiment Signal: Sell
Current Market Cap: A$413.3M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.